Načítá se...
Radioactive Iodine Resistant Papillary Thyroid Cancer “Redifferentiated” With Dabrafenib
Background: Differentiated thyroid cancers (DTC) make up 95% of all thyroid cancers. Radioactive iodine therapy (RAI Rx) is an integral part of DTC management. However, 5-15% of DTC and 50% of metastatic DTC become resistant to RAI Rx and carries a 10-year survival of only 10%. One of the newer ther...
Uloženo v:
| Vydáno v: | J Endocr Soc |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8090069/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1833 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|